Acrivon Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRV research report →
Range $17 – $30
Price Chart
About the company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification.
- CEO
- Peter Blume-Jensen
- IPO
- 2022
- Employees
- 75
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on ACRV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $94.16M
- P/E
- -1.17
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 1.06
- EV/EBITDA
- -0.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -70.14%
- ROIC
- -88.28%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,356,000-34.8%
- Op Income
- $-84,114,000
- Net Income
- $-77,905,000+3.3%
- EPS
- $-2.02+3.8%
- OCF Growth
- +3.1%
- FCF Growth
- +4.5%
- 52W High
- $3.56
- 52W Low
- $1.27
- 50D MA
- $1.72
- 200D MA
- $1.86
- Beta
- 1.86
- RSI (14)
- 67
- Avg Volume
- 419.71K
No earnings-call transcripts are available for ACRV yet.
- Free Float
- 65.3%
- Shares Outstanding
- 42.80M
- Float Shares
- 27.93M
of shares held by institutions
48 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 698.86K | ▲ 72.71K |
| Two Sigma Advisers, LP | 333.77K | ▲ 197.27K |
Held by 22 ETFs
Biggest fund positions in ACRV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | Peterson Katharine | sell | 101 |
| Aug 18, 26 | Miller Mary | sell | 185 |
| Aug 18, 26 | Gamelin Erick | sell | 400 |
| Aug 18, 26 | Devroe Eric | sell | 604 |
| Aug 18, 26 | Blume-Jensen Peter | sell | 1,229 |
| Aug 18, 26 | Blume-Jensen Peter | sell | 484 |
| Aug 4, 26 | Levy Adam D. | sell | 1,142 |
| Jul 21, 26 | Miller Mary | sell | 573 |
| Jun 17, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 20,275 |
| Jun 17, 26 | TOMSICEK MICHAEL JOHN | other | 20,275 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACRV coverage
Recent articles, reports, and earnings notes.
No research on ACRV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACRV report →Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
globenewswire.com · Aug 12
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
globenewswire.com · Aug 5
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
globenewswire.com · Jul 21
Acrivon Therapeutics: Priced For Failure, Built For Precision
seekingalpha.com · Jul 13
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
globenewswire.com · May 21
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 15
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
globenewswire.com · May 13
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
globenewswire.com · Apr 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.